GLP-1 Analogs & Incretin Compounds
GLP-1R · GIPR · GCGR · Incretin Biology · Metabolic Research
The GLP-1 analog and incretin compound family represents the most clinically active area of peptide pharmacology as of 2024, with multiple approved single- and dual-agonist drugs and pipeline triple-agonists under Phase III evaluation. At Genesis Genetics, this family is anchored by Retatrutide (LY3437943), a GLP-1/GIP/Glucagon triple receptor agonist developed by Eli Lilly whose Phase II trial data showed remarkable efficacy in obesity models.
Compounds in This Family
Overview
GLP-1 (glucagon-like peptide-1) is an incretin hormone released from gut L-cells in response to nutrient ingestion. Its receptor (GLP-1R) is expressed on pancreatic beta cells, CNS neurons, cardiac tissue, and adipocytes. GLP-1R agonism drives glucose-dependent insulin secretion, reduces glucagon release, slows gastric emptying, and promotes satiety via vagal and central mechanisms. The addition of GIP receptor (GIPR) agonism in tirzepatide-class compounds adds incretin-mediated insulin secretion. The further addition of glucagon receptor (GCGR) agonism in retatrutide-class compounds adds direct energy expenditure stimulation and hepatic glucose effects.
Research with incretin compounds spans metabolic disease pharmacology, receptor structure-function studies, cardiovascular biology, CNS appetite regulation, and liver biology. The availability of GLP-1R agonists with increasing receptor profile complexity (mono, dual, triple) enables systematic study of additive versus synergistic receptor interactions in metabolic models.
Research Themes
Triple Receptor Agonism and Weight Loss Mechanisms
Retatrutide's co-activation of GLP-1R, GIPR, and GCGR provides a research tool for studying how glucagon receptor agonism adds to the weight loss effects of dual incretin agonism. The ~17-24% body weight reduction seen in Phase II trials exceeds Phase II results for GLP-1-only and dual GLP-1/GIP agonists, suggesting synergistic rather than merely additive receptor interactions. Research with retatrutide can help determine what proportion of this additional effect comes from increased energy expenditure (GCGR-mediated) versus enhanced satiety or insulin sensitivity.
Incretin Receptor Structure-Function Research
All three receptors targeted by retatrutide (GLP-1R, GIPR, GCGR) are class B1 GPCRs with structurally related N-terminal extracellular domains. Research with mono-, dual-, and triple-agonist peptides has been instrumental in understanding the structural basis of receptor selectivity and has informed computational modeling of GPCR binding. Retatrutide's fatty acid modification (enabling ~6-day half-life via albumin binding) also makes it a useful model for studying long-acting GPCR agonist pharmacology.
Hepatic Metabolism and Glucagon Receptor Biology
The glucagon receptor component of retatrutide's pharmacology introduces hepatic glucose production and lipid metabolism effects that GLP-1-only agonists lack. GCGR agonism in the liver stimulates glycogenolysis and gluconeogenesis through cAMP/PKA pathways. In the context of obesity research, this hepatic activation appears to contribute to energy expenditure without causing diabetogenic hyperglycemia when co-administered with GLP-1R agonism — making the combination an interesting subject for studying hepatic-pancreatic glucose balance.
Compound Research Overviews
Frequently Asked Questions
How does Retatrutide differ from semaglutide and tirzepatide?+
Semaglutide is a GLP-1R mono-agonist. Tirzepatide is a dual GLP-1R/GIPR agonist. Retatrutide is a triple GLP-1R/GIPR/GCGR agonist. The glucagon receptor (GCGR) component is the critical addition in retatrutide, which is hypothesized to drive additional energy expenditure through hepatic and thermogenic mechanisms that the other two lack. This is reflected in the more pronounced weight reduction observed in retatrutide's Phase II data compared to published Phase II data for the other compounds.
Is GLP-1 related to glucagon? How can agonizing both be beneficial?+
GLP-1 and glucagon are both derived from the proglucagon gene but have opposing effects on blood glucose — GLP-1 stimulates insulin release (lowering glucose) while glucagon raises blood glucose. The apparent paradox of activating both is resolved by GLP-1R agonism creating a baseline insulin-sensitized state in which glucagon receptor activation drives energy expenditure without causing hyperglycemia. This insulin-glucagon balance is an active research area in metabolic pharmacology.
What is Retatrutide's current regulatory status?+
As of 2024, retatrutide is in Phase III clinical trials for obesity. It is not approved for human therapeutic use in any jurisdiction. It is available at Genesis Genetics for research purposes only — preclinical studies examining receptor pharmacology, metabolic pathways, or comparative incretin biology in appropriate in vitro and in vivo research models.
Research Use Only. All compounds in the GLP-1 Analogs & Incretin Compounds family are sold for laboratory and research applications only and are not approved for human or veterinary therapeutic use. Information presented on this page is derived from published preclinical and clinical research literature and is provided for educational and scientific context only.
Other Peptide Families